Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.26 USD | +2.55% | +1.54% | +1.42% |
Financials (USD)
Sales 2024 * | 43.3M | Sales 2025 * | 165M | Capitalization | 542M |
---|---|---|---|---|---|
Net income 2024 * | -261M | Net income 2025 * | -220M | EV / Sales 2024 * | 8.02 x |
Net cash position 2024 * | 195M | Net cash position 2025 * | 89.8M | EV / Sales 2025 * | 2.74 x |
P/E ratio 2024 * |
-2.12
x | P/E ratio 2025 * |
-2.78
x | Employees | 452 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.33% |
Latest transcript on Phathom Pharmaceuticals, Inc.
1 day | +2.55% | ||
1 week | +1.54% | ||
Current month | +2.55% | ||
1 month | -12.64% | ||
3 months | +39.04% | ||
6 months | -3.64% | ||
Current year | +1.42% |
Managers | Title | Age | Since |
---|---|---|---|
Azmi Nabulsi
FOU | Founder | 64 | 18-01-08 |
Terrie Curran
CEO | Chief Executive Officer | 55 | 19-07-31 |
David Socks
FOU | Founder | 49 | 18-01-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Heidi Fields
BRD | Director/Board Member | 69 | 19-09-26 |
Frank Karbe
BRD | Director/Board Member | 56 | 22-04-24 |
Michael Cola
CHM | Chairman | 64 | 19-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.02% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 9.26 | +2.55% | 512,297 |
24-04-30 | 9.03 | -3.42% | 414,106 |
24-04-29 | 9.35 | +1.85% | 431,026 |
24-04-26 | 9.18 | +0.88% | 370,890 |
24-04-25 | 9.1 | -0.22% | 544,924 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.42% | 542M | |
+0.67% | 42.4B | |
+46.40% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- PHAT Stock